Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
Open Access
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 28 (10), 2511-2516
- https://doi.org/10.1093/annonc/mdx353
Abstract
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial. The R-CHOP 14 versus 21 trial compared R-CHOP administered two- versus three weekly in previously untreated patients aged ≥18 years with bulky stage I–IV DLBCL (n = 1080). Details of CNS prophylaxis were retrospectively collected from participating sites. The incidence and risk factors for CNS relapse including application of the CNS-IPI were evaluated. 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate (MTX) n = 163, intravenous (IV) MTX n = 2, prophylaxis type unknown n = 11 and IT MTX and cytarabine n = 1). At a median follow-up of 6.5 years, 21 cases of CNS relapse (isolated n = 11, with systemic relapse n = 10) were observed, with a cumulative incidence of 1.9%. For patients selected to receive prophylaxis, the incidence was 2.8%. Relapses predominantly involved the brain parenchyma (81.0%) and isolated leptomeningeal involvement was rare (14.3%). Univariable analysis demonstrated the following risk factors for CNS relapse: performance status 2, elevated lactate dehydrogenase, IPI, >1 extranodal site of disease and presence of a ‘high-risk’ extranodal site. Due to the low number of events no factor remained significant in multivariate analysis. Application of the CNS-IPI revealed a high-risk group (4-6 risk factors) with a 2- and 5-year incidence of CNS relapse of 5.2% and 6.8%, respectively. Despite very limited use of IV MTX as prophylaxis, the incidence of CNS relapse following R-CHOP was very low (1.9%) confirming the reduced incidence in the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence. ISCRTN number 16017947 (R-CHOP14v21); EudraCT number 2004-002197-34.Keywords
Funding Information
- National Institutes of Health (CRUKE/03/019)
- Cancer Research UK
This publication has 25 references indexed in Scilit:
- Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in HaematologyBritish Journal of Haematology, 2013
- Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysisLeukemia & Lymphoma, 2013
- Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literatureBritish Journal of Haematology, 2012
- The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B‐cell lymphomaBritish Journal of Haematology, 2012
- Prevention of CNS relapse in diffuse large B-cell lymphomaThe Lancet Oncology, 2011
- Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab eraCancer, 2011
- Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapyAnnals Of Oncology, 2009
- CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)Blood, 2009
- Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experienceInternational Journal of Hematology, 2009
- Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximabAnnals of Oncology, 2004